Mounjaro, a new diabetes medication that risks being misused, is now on sale in Belgium. This treatment, which also helps fight obesity, raises concerns about the risk of shortage. Discover the impacts of this new drug and the issues linked to its arrival on the pharmaceutical market.
A new drug for diabetics, Mounjaro, is now available in Belgium, offering hope to patients suffering from type 2 diabetes. This drug, similar to its predecessor Ozempic, is also effective in the fight against obesity, but this double action carries risks of diversion from its initial use, warns a series of experts.
Frédéric, 54 years old, testifies to the benefits of Mounjaro in the management of his diabetes and his excess weight. Having lost nearly 22 kilos in three months thanks to this treatment, he highlights the positive impact on his daily life. The drug, recently authorized in Belgium, is generating real enthusiasm among patients and healthcare professionals.
However, the arrival of Mounjaro on the Belgian pharmaceutical market raises concerns about the possibility of shortages. Indeed, Mounjaro is presented as an alternative to similar drugs, such as Ozempic, which are already experiencing supply difficulties. This tense situation on the market for anti-diabetic drugs has raised concerns among the population and health professionals.
These concerns are heightened by the risk of misuse of Mounjaro for cosmetic weight loss purposes, when the drug should only be prescribed for medical reasons. Indeed, inappropriate use of this type of treatment can worsen the current shortage and present risks to patients’ health.
Mounjaro, although offering significant advances in the treatment of diabetes and obesity, therefore represents a challenge for health authorities in terms of regulating and monitoring its use. It remains essential to raise awareness among the population about good practices and to guarantee equitable access to this medicine for patients truly concerned by its benefits.
diabetes Mounjaro obesity shortage
